Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a)
Inflammation
0301 basic medicine
Membrane Glycoproteins
Antibodies, Monoclonal
Immunoglobulins
Nitric Oxide Synthase Type II
Cell Separation
Dendritic Cells
HLA-DR Antigens
Antibodies, Monoclonal, Humanized
Flow Cytometry
Immunohistochemistry
Lysosomal Membrane Proteins
CD11c Antigen
03 medical and health sciences
Microscopy, Fluorescence
Antigens, CD
Humans
Psoriasis
B7-2 Antigen
RNA, Messenger
CD40 Antigens
DOI:
10.1073/pnas.0509736102
Publication Date:
2005-12-27T17:52:37Z
AUTHORS (18)
ABSTRACT
We find that CD11c
+
cells with many markers of dendritic cells (DCs) are a major cell type in the skin lesions of psoriasis. These CD11c
+
cells, which are evident in both epidermis and dermis, are the sites for the expression of two mediators of inflammation, inducible nitric oxide synthase (iNOS) and TNF-α in diseased skin. These cells express HLA-DR, CD40, and CD86, lack the Langerin and CD14 markers of Langerhans cells and monocytes, respectively, and to a significant extent express the DC maturation markers DC-LAMP and CD83. Treatment of psoriasis with efalizumab (anti-CD11a, Raptiva) strongly reduces infiltration by these DCs in patients responding to this agent. Disease activity after therapy was more related to DC infiltrates and iNOS mRNA levels than T cell infiltrates, and CD11c
+
cells responded more quickly to therapy than epidermal keratinocytes. Our results suggest that a type of DC, which resembles murine “Tip-DCs” that can accumulate during infection, has proinflammatory effects in psoriasis through nitric oxide and TNF-α production, and can be an important target for suppressive therapies.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (32)
CITATIONS (387)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....